| Literature DB >> 31904167 |
Isidro Machado1, Gema Nieto-Morales2, Julia Cruz1, Samuel Navarro3, Francisco Giner4, Antonio Ferrandez3, María Victoria López-Soto5, Javier Lavernia6, Antonio Llombart-Bosch3.
Abstract
The clinical evolution of solitary fibrous tumor (SFT) remains unclear. Although various clinical, morphological and molecular criteria may indicate increased risk of malignancy, some SFT can still progress despite having a clearly benign appearance. Various risk stratification systems have been proposed, but unfortunately they are not sufficient to precisely determine the malignant potential. In this review, we discuss current knowledge on SFT, focusing on the following controversial issues: (i) the diverse morphologic spectrum: 'the great simulator;' (ii) malignant transformation or dedifferentiation; (iii) current risk stratification systems; and (iv) molecular factors associated with clinical evolution. The morphological spectrum of SFT and the list of differential diagnoses continue to expand. Both have increased considerably since the first descriptions of specific molecular alterations. A classification of malignant SFT should not be based on histology alone. The correlation of all pathological and molecular factors is recommended; its inclusion in risk stratification systems may help to improve diagnosis and prognosis.Entities:
Keywords: immunohistochemistry; molecular biology and risk stratification systems; morphology; solitary fibrous tumor
Year: 2020 PMID: 31904167 DOI: 10.1111/pin.12894
Source DB: PubMed Journal: Pathol Int ISSN: 1320-5463 Impact factor: 2.534